Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HLN 
Haleon plc (HLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.59
1 Year Target Price $11.59
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.37% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 43.43B USD | Price to earnings Ratio 21.53 | 1Y Target Price 11.59 |
Price to earnings Ratio 21.53 | 1Y Target Price 11.59 | ||
Volume (30-day avg) 5 | Beta 0.24 | 52 Weeks Range 8.70 - 11.35 | Updated Date 08/29/2025 |
52 Weeks Range 8.70 - 11.35 | Updated Date 08/29/2025 | ||
Dividends yield (FY) 0.70% | Basic EPS (TTM) 0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-07-31 | When Before Market | Estimate 0.1066 | Actual 0.09 |
Profitability
Profit Margin 13.81% | Operating Margin (TTM) 22.21% |
Management Effectiveness
Return on Assets (TTM) 4.61% | Return on Equity (TTM) 9.38% |
Valuation
Trailing PE 21.53 | Forward PE 19.46 | Enterprise Value 54052480464 | Price to Sales(TTM) 3.94 |
Enterprise Value 54052480464 | Price to Sales(TTM) 3.94 | ||
Enterprise Value to Revenue 3.63 | Enterprise Value to EBITDA 14.76 | Shares Outstanding 4482449920 | Shares Floating 8953298501 |
Shares Outstanding 4482449920 | Shares Floating 8953298501 | ||
Percent Insiders 0.02 | Percent Institutions 12.83 |
Upturn AI SWOT
Haleon plc
Company Overview
History and Background
Haleon plc was formed in July 2022 as a spin-off from GSK (GlaxoSmithKline). It focuses exclusively on consumer healthcare products. GSK and Pfizer initially held significant stakes.
Core Business Areas
- Oral Health: This segment focuses on products like toothpaste, toothbrushes, and mouthwash under brands such as Sensodyne, Parodontax, and Polident. It maintains a strong global presence and innovation in specialized oral care solutions.
- Vitamins, Minerals and Supplements: This segment includes brands like Centrum, Caltrate, and Emergen-C. It focuses on providing products to support overall health and well-being, addressing various nutritional needs.
- Pain Relief: This segment offers over-the-counter pain relief medications under brands like Panadol, Advil and Voltaren. These products provide relief from various types of pain, including headaches, muscle aches, and joint pain.
- Respiratory Health: This segment provides solutions for respiratory conditions, including cold, flu and allergy symptoms. Brands include Theraflu and Robitussin.
- Digestive Health and Other: This segment includes products for digestive health issues and other general health needs. Brands such as TUMS and ENO.
Leadership and Structure
Brian McNamara serves as the CEO. The company operates with a functional organizational structure, emphasizing efficiency and specialization across its various business units.
Top Products and Market Share
Key Offerings
- Sensodyne: Sensodyne is a leading toothpaste brand for sensitive teeth. Global market share is estimated at over 20%. Competitors include Colgate Sensitive and Crest Pro-Health Sensitive. Revenue data for individual products is not typically disclosed.
- Panadol: Panadol (paracetamol/acetaminophen) is a widely used pain reliever. It holds significant market share in many regions globally, competing with brands like Tylenol (JNJ) and generic acetaminophen. Revenue data for individual products is not typically disclosed.
- Advil: Advil (ibuprofen) is a popular nonsteroidal anti-inflammatory drug (NSAID). Global market share is estimated around 10%. Competitors include Motrin (JNJ) and generic ibuprofen. Revenue data for individual products is not typically disclosed.
- Centrum: Centrum is a leading multivitamin brand. Global market share is significant. Competitors include One A Day (BAYRY) and generic multivitamins. Revenue data for individual products is not typically disclosed.
Market Dynamics
Industry Overview
The consumer healthcare industry is characterized by increasing self-care trends, an aging population, and a growing demand for preventative health solutions. The market is competitive with strong players and increasing private label presence.
Positioning
Haleon plc is a global leader in consumer healthcare, with a strong portfolio of trusted brands. Its competitive advantages include brand recognition, established distribution networks, and a focus on innovation.
Total Addressable Market (TAM)
The global consumer healthcare market is estimated to be worth over $250 billion. Haleon plc is well-positioned to capture a significant portion of this market due to its diverse product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand portfolio
- Global presence and distribution network
- Focus on innovation and R&D
- Established market leadership in key segments
Weaknesses
- High debt levels from spin-off
- Dependence on key brands
- Exposure to regulatory risks
- Integration risks from acquisitions
Opportunities
- Expanding into emerging markets
- Developing new products and formulations
- Acquiring complementary businesses
- Leveraging digital channels for marketing and sales
Threats
- Increasing competition from private label brands
- Changing consumer preferences
- Regulatory changes and pricing pressures
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PG
- BAYRY
- SANOY
Competitive Landscape
Haleon has a strong presence in oral care and pain relief, while JNJ and PG compete across multiple consumer health categories. Bayer focuses more on vitamins and supplements. SANOY focuses more on cough and cold products. Haleon is seeking to strengthen its market leadership through innovation and strategic acquisitions.
Major Acquisitions
Dr. Will's
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: Dr. Will's has natural oral health products. The acquisition allows Haleon to expand its portfolio of natural oral care products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on prior years and requires updated data. Requires data updates to be accurate
Future Projections: Analyst projections vary and require continuous updates. Requires data updates to be accurate
Recent Initiatives: Recent strategic initiatives include focusing on innovation in key categories, expanding digital marketing efforts, and optimizing the supply chain. Details can be found on Haleon's website.
Summary
Haleon is a leading consumer healthcare company with a strong brand portfolio and global presence. The company benefits from the increasing self-care trend and an aging population. High debt and changing consumer preferences are challenges that it needs to watch out for. Successful innovation and acquisitions will be key to future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. The AI-based rating is based on a specific algorithm and should not be considered definitive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Haleon plc
Exchange NYSE | Headquaters - | ||
IPO Launch date 2022-07-22 | CEO & Executive Director Mr. Brian James McNamara | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 24561 | Website https://www.haleon.com |
Full time employees 24561 | Website https://www.haleon.com | ||
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.